Role of β-lactamase Inhibitors on Cefiderocol Activity Against Carbapenem-resistant Acinetobacter Species

Overview

Journal Int J Antimicrob Agents

Specialties Infectious Diseases
Pharmacology

Date 2022 Dec 5

PMID 36470509

Authors

Vyanka Mezcord

Olivia Wong

Fernando Pasteran

Alejandra Corso

Marcelo E Tolmasky

Robert A Bonomo

Maria Soledad Ramirez

Affiliations

Soon will be listed here.

Citing Articles

Breakthrough Advances in Beta-Lactamase Inhibitors: New Synthesized Compounds and Mechanisms of Action Against Drug-Resistant Bacteria.

Huang Y, Zhou H Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006020 PMC: 11859904. DOI: 10.3390/ph18020206.

Cefiderocol in Combating Carbapenem-Resistant : Action and Resistance.

Yousefi B, Kashanipoor S, Mazaheri P, Alibabaei F, Babaeizad A, Asli S Biomedicines. 2024; 12(11).

PMID: 39595098 PMC: 11592056. DOI: 10.3390/biomedicines12112532.

Challenges Facing Two Outbreaks of Carbapenem-Resistant : From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants.

Rodriguez-Aguirregabiria M, Lazaro-Perona F, Cacho-Calvo J, Arellano-Serrano M, Ramos-Ramos J, Rubio-Mora E Antibiotics (Basel). 2024; 13(8).

PMID: 39200084 PMC: 11350900. DOI: 10.3390/antibiotics13080784.

Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant spp.

Wong O, Mezcord V, Lopez C, Traglia G, Pasteran F, Tuttobene M Microbiol Spectr. 2024; 12(10):e0093024.

PMID: 39162493 PMC: 11448186. DOI: 10.1128/spectrum.00930-24.

Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant spp.

Wong O, Mezcord V, Lopez C, Traglia G, Pasteran F, Tuttobene M bioRxiv. 2024; .

PMID: 38496545 PMC: 10942374. DOI: 10.1101/2024.03.04.583376.

References

Ruggiero M, Papp-Wallace K, Taracila M, Mojica M, Bethel C, Rudin S . Exploring the Landscape of Diazabicyclooctane (DBO) Inhibition: Avibactam Inactivation of PER-2 β-Lactamase. Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444126. DOI: 10.1128/AAC.02476-16. View

Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R . Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3.... Lancet Infect Dis. 2020; 21(2):226-240. DOI: 10.1016/S1473-3099(20)30796-9. View

Pasteran F, Cedano J, Baez M, Albornoz E, Rapoport M, Osteria J . A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant (CRAB) Isolates. Antibiotics (Basel). 2021; 10(5). PMC: 8152955. DOI: 10.3390/antibiotics10050577. View

Barnes M, Kumar V, Bethel C, Moussa S, ODonnell J, Rutter J . Targeting Multidrug-Resistant spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent. mBio. 2019; 10(2). PMC: 6414696. DOI: 10.1128/mBio.00159-19. View

Poirel L, Sadek M, Nordmann P . Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2021; 65(10):e0087721. PMC: 8448131. DOI: 10.1128/AAC.00877-21. View